AU
CA
NZ
UK
US
IND
Last update at 2026-03-10T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Benzinga's Top Upgrades, Downgrades For December 23, 2020
Wed 23 Dec 20, 03:07 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -113.59700M | -121.74800M | -93.25700M | -85.47200M | -56.94600M |
| Minority interest | - | - | - | - | - |
| Net income | -114.52700M | -122.17600M | -93.66600M | -85.66200M | -53.85400M |
| Selling general administrative | 29.91M | 31.75M | 22.27M | 23.23M | 18.22M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | - | - | 0.00000M |
| Reconciled depreciation | 2.06M | 2.22M | 2.03M | 1.76M | 1.94M |
| Ebit | -108.46600M | -115.39600M | -93.91200M | -88.12100M | -60.03800M |
| Ebitda | -108.40500M | -114.91000M | -91.88600M | -86.35700M | -58.10300M |
| Depreciation and amortization | 0.06M | 0.49M | 2.03M | 1.76M | 1.94M |
| Non operating income net other | - | -6.35200M | -1.37100M | 1.07M | 1.16M |
| Operating income | -108.46600M | -115.39600M | -91.88600M | -86.35700M | -58.10300M |
| Other operating expenses | 108.47M | 115.40M | 91.89M | 86.36M | 58.10M |
| Interest expense | 4.67M | 3.61M | 2.11M | 1.05M | 1.56M |
| Tax provision | 0.93M | 0.43M | 0.41M | 0.19M | - |
| Interest income | - | - | - | 1.05M | 1.56M |
| Net interest income | -4.67200M | -3.61200M | -2.10900M | 1.05M | 1.56M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.93M | 0.43M | 0.41M | 0.19M | -3.09200M |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 108.47M | 115.40M | 91.89M | 86.36M | 58.10M |
| Cost of revenue | - | - | - | - | 0.00000M |
| Total other income expense net | -5.13100M | -6.35200M | -1.37100M | 0.89M | 1.16M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -114.52700M | -122.17600M | -93.66600M | -85.47200M | -56.94600M |
| Net income applicable to common shares | -114.52700M | -122.17600M | -93.66600M | -85.47200M | -60.88300M |
| Preferred stock and other adjustments | - | - | - | - | 3.94M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 64.44M | 87.87M | 90.64M | 90.92M | 159.87M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.63M | 2.58M | 2.12M | 3.18M | 3.70M |
| Total liab | 69.43M | 79.20M | 60.15M | 30.72M | 22.92M |
| Total stockholder equity | -4.99200M | 8.67M | 30.48M | 60.20M | 136.95M |
| Deferred long term liab | - | 7.50M | - | 1.15M | 1.07M |
| Other current liab | 0.87M | 0.74M | 0.46M | 9.12M | 7.72M |
| Common stock | 0.11M | 0.05M | 0.05M | 0.03M | 0.03M |
| Capital stock | 0.11M | 0.05M | 0.05M | 0.03M | 0.03M |
| Retained earnings | -529.22200M | -414.69500M | -292.51900M | -198.85300M | -113.38100M |
| Other liab | 8.16M | 7.50M | 0.28M | 1.35M | 1.38M |
| Good will | - | - | - | - | - |
| Other assets | 1.16M | 1.31M | 12.18M | 1.57M | 1.32M |
| Cash | 47.94M | 68.44M | 68.86M | 77.83M | 147.92M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 12.39M | 17.36M | 19.83M | 9.74M | 9.23M |
| Current deferred revenue | 7.50M | 13.07M | -2.13700M | - | - |
| Net debt | 3.20M | -12.14800M | -28.82000M | -58.19900M | -135.61400M |
| Short term debt | 2.26M | 1.95M | 1.67M | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 51.14M | 56.29M | 40.04M | 19.63M | 12.30M |
| Other stockholder equity | 524.12M | 423.31M | 322.96M | 259.02M | 90.45M |
| Property plant equipment | 11.71M | 6.62M | 7.48M | 8.34M | 6.92M |
| Total current assets | 51.57M | 71.03M | 68.86M | 77.83M | 147.92M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | -4.99200M | 8.67M | 30.48M | 60.20M | 136.95M |
| Short term investments | - | - | - | 0.00000M | 54.82M |
| Net receivables | - | - | - | - | - |
| Long term debt | 43.61M | 46.56M | 30.05M | 19.63M | 12.30M |
| Inventory | - | - | - | - | - |
| Accounts payable | 1.76M | 1.60M | 19.83M | 9.74M | 9.23M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -90.92000M | -0.01800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.05M | 0.05M | 0.03M | 0.03M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -414.69500M | -292.51900M | -198.85300M | -113.38100M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.16M | 1.31M | 3.55M | 4.75M | 5.02M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 12.87M | 16.84M | 21.78M | 13.09M | 11.95M |
| Capital lease obligations | 7.52M | 9.74M | 11.66M | - | - |
| Long term debt total | - | 46.56M | 30.05M | 19.63M | 12.30M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.62200M | -1.48100M | -1.31500M | 55.00M | -54.83700M |
| Change to liabilities | 0.17M | -2.88300M | 8.48M | 3.10M | 4.22M |
| Total cashflows from investing activities | -0.62200M | -1.48100M | -1.31500M | 51.97M | -60.12800M |
| Net borrowings | -3.12300M | 14.78M | 10.00M | 4.48M | 4.72M |
| Total cash from financing activities | 81.66M | 97.54M | 65.47M | 4.99M | 162.01M |
| Change to operating activities | -9.83600M | -5.59100M | 6.93M | 4.06M | 1.39M |
| Net income | -114.52700M | -122.17600M | -93.66600M | -85.47200M | -56.94600M |
| Change in cash | -20.65600M | -0.66600M | -8.91300M | -15.01800M | 54.60M |
| Begin period cash flow | 69.75M | 70.42M | 79.33M | 94.35M | 39.75M |
| End period cash flow | 49.10M | 69.75M | 70.42M | 79.33M | 94.35M |
| Total cash from operating activities | -101.23500M | -96.72500M | -73.06300M | -71.98000M | -47.27900M |
| Issuance of capital stock | 84.54M | 81.75M | 54.99M | 0.00000M | 157.16M |
| Depreciation | 2.06M | 2.22M | 2.03M | 1.76M | 1.94M |
| Other cashflows from investing activities | - | 0.04M | 0.00600M | 0.00200M | 0.17M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | - | 1.01M | 55.47M | 0.51M | 0.12M |
| Other cashflows from financing activities | 44.72M | 15.79M | 10.47M | 19.99M | 86.18M |
| Change to netincome | 20.90M | 19.32M | 8.84M | 8.42M | 6.57M |
| Capital expenditures | 0.62M | 1.52M | 1.32M | 3.03M | 5.46M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | 6.80M | 1.26M | 0.37M | -3.05200M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -0.66600M | -8.91300M | -15.01800M | 54.60M |
| Change in working capital | -9.66600M | 2.07M | 7.76M | 3.47M | 1.16M |
| Stock based compensation | 15.16M | 15.85M | 8.47M | 8.16M | 6.06M |
| Other non cash items | 5.74M | 2.10M | 2.35M | 0.26M | 0.10M |
| Free cash flow | -101.85700M | -98.24400M | -74.38400M | -75.01200M | -52.74100M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| EVLO Evelo Biosciences Inc |
- -% | 0.0005 | - | - | - | 3.51 | -0.2364 | |
| NVO Novo Nordisk A/S |
0.16 0.41% | 38.88 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
0.005 0.01% | 38.74 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.89 0.98% | 494.28 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
3.71 0.48% | 775.75 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
620 Memorial Drive, Cambridge, MA, United States, 02139
| Name | Title | Year Born |
|---|---|---|
| Dr. Balkrishan Gill Ph.D. | Pres, CEO & Director | 1965 |
| Dr. Jonathan B. Zung Ph.D. | Chief Devel. Officer | 1965 |
| Ms. Marella Thorell | CFO & Treasurer | 1967 |
| Mr. Stephen J. Carriere | VP & Chief Accounting Officer | 1955 |
| Dr. Chun Zhang Ph.D. | Chief Technical Operations & Quality Officer | NA |
| Dr. Mark Bodmer Ph.D. | Chief Scientific Officer and Pres of R&D | 1958 |
| Ms. Kendra Sweeney | Head of Investor Relations & Capital Markets | NA |
| Ms. Jessica Cotrone | VP & Head of Communications | NA |
| Ms. Leslie Wardwell-Scott Ph.D. | VP and Head of Corp. Devel. & Strategic Integration | NA |
| Ms. Julie Carretero | Chief People Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...